Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis.
Nickel JC, Pontari M, Moon T, Gittelman M, Malek G, Farrington J, Pearson J, Krupa D, Bach M, Drisko J; Rofecoxib Prostatitis Investigator Team. Nickel JC, et al. Among authors: gittelman m. J Urol. 2003 Apr;169(4):1401-5. doi: 10.1097/01.ju.0000054983.45096.16. J Urol. 2003. PMID: 12629372 Clinical Trial.
Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.
Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, Melman A, Bracken RB, deVere White R, Taylor A, Wang D, Waldstreicher J. Roehrborn CG, et al. Among authors: gittelman m. Urology. 1999 Oct;54(4):662-9. doi: 10.1016/s0090-4295(99)00232-0. Urology. 1999. PMID: 10510925 Clinical Trial.
Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial.
Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H; Vardenafil Study Group. Hellstrom WJ, et al. Among authors: gittelman m. Urology. 2003 Apr;61(4 Suppl 1):8-14. doi: 10.1016/s0090-4295(03)00115-8. Urology. 2003. PMID: 12657355 Clinical Trial.
Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J; Proscar Long-Term Efficacy and Safety Study Group. Roehrborn CG, et al. J Urol. 2004 Mar;171(3):1194-8. doi: 10.1097/01.ju.0000112918.74410.94. J Urol. 2004. PMID: 14767299 Clinical Trial.
Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study.
Porst H, Sharlip ID, Hatzichristou D, Rubio-Aurioles E, Gittelman M, Stancil BN, Smith PM, Wilkins HJ, Pommerville P; Vardenafil Study Group. Porst H, et al. Among authors: gittelman m. Eur Urol. 2006 Nov;50(5):1086-94; discussion 1094-5. doi: 10.1016/j.eururo.2006.05.036. Epub 2006 Jun 8. Eur Urol. 2006. PMID: 16820261 Clinical Trial.
An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study.
Hellstrom WJ, Gittelman M, Jarow J, Steidle C, McMurray J, Talley D, Watts S, Mitchell CL, McGill JM. Hellstrom WJ, et al. Among authors: gittelman m. Eur Urol. 2008 May;53(5):1058-65. doi: 10.1016/j.eururo.2007.09.046. Epub 2007 Oct 5. Eur Urol. 2008. PMID: 17945409 Clinical Trial.
146 results